CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly .
Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business.
On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab.
"I think this advisory committee decision on their Alzheimer's drug does precisely that."
Eli Lilly did not immediately respond to request for comment.
Persons:
CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've
Organizations:
Food and Drug Administration, FDA
Locations:
U.S, Biogen